StocksMarket.in

Trading Calls - Equity F&O

Buy Oil India; target of Rs 200: Sharekhan

Sharekhan’s research report on Oil India Q1FY2020 adjusted PAT lagged our estimates due to miss in net oil realisation and lower-than-expected oil and gas sales volume. We have cut

Read Full Article

Buy Sadbhav Engineering; target of Rs 200: Sharekhan

Sharekhan’s research report on Sadbhav Engineering Q1 earnings were affected by a delay in receipt of appointed dates of hybrid-annuity projects (HAM) projects dragging down standalone net profit by

Read Full Article

Buy Century Plyboards (India); target of Rs 190: Sharekhan

Sharekhan’s research report on Century Plyboards (India) In Q1FY2020, Century reported strong sequential improvement in OPM across verticals, leading to 49% q-o-q growth in standalone net earnings. Management is

Read Full Article

Buy Thyrocare Technologies; target of Rs 595: Prabhudas Lilladher

Prabhudas Lilladher’s research report on Thyrocare Technologies Thyrocar’s sales grew 13% YoY, EBITDA grew 11% Yoy and PAT increased by 16% YoY in Q1FY20. The growth in preventive care

Read Full Article

Buy Engineers India; target of Rs 139: Prabhudas Lilladher

Prabhudas Lilladher’s research report on Engineers India Engineers India Ltd (EIL) reported good set of numbers for 1QFY20, led by higher contribution coming from Consultancy Segment. Revenue/PAT up 28%/43%

Read Full Article

Diamonds in the dust | This FMCG company has an ability to compound that long term investors may like

To view the full content of this article, you have to be a Pro: Subscribe to Moneycontrol Pro: What’s included:

Read Full Article

Hold AIA Engineering; target of Rs 1785: ICICI Direct

ICICI Direct’s research report on AIA Engineering AIA Engineering (AIA) reported revenues at Rs 733.3 crore (vs. estimate of

Read Full Article

Hold United Breweries; target of Rs 1500: ICICI Direct

ICICI Direct’s research report on United Breweries United Breweries (UBL) grew 10% YoY in Q1FY20 with volume growth of

Read Full Article

Hold Glenmark Pharmaceuticals; target of Rs 410: ICICI Direct

ICICI Direct’s research report on Glenmark Pharmaceuticals Q1 revenues grew 7.3% YoY to rs 2322.9 crore (I-direct estimate: rs

Read Full Article

Hold NRB Bearings; target of Rs 85: ICICI Direct

ICICI Direct’s research report on NRB Bearings NRB Bearings reported a weak performance across all operational parameters. Standalone revenues

Read Full Article

Buy EIH; target of Rs 200: ICICI Direct

ICICI Direct’s research report on EIH EIH reported a weak set of results mainly on account of the weak

Read Full Article

IRCON International: An attractive investment idea that’s a bet on Railways capex

NULL

Read Full Article

Hold IRB Infrastructure; target of Rs 100: ICICI Direct

ICICI Direct’s research report on IRB Infrastructure IRB Infrastructure’s (IRB) topline grew 15.3% YoY to Rs 1,773.0 crore on

Read Full Article

Hold TTK Prestige; target of Rs 6580: ICICI Direct

ICICI Direct’s research report on TTK Prestige TTK Prestige reported a moderate set of numbers, with numbers coming in

Read Full Article

Hold Wonderla Holidays; target of Rs 285: ICICI Direct

ICICI Direct’s research report on Wonderla Holidays On the back of healthy footfalls growth, Wonderla reported a positive set

Read Full Article

Hold Engineers India; target of Rs 105: ICICI Direct

ICICI Direct’s research report on Engineers India Engineers India (EIL) reported strong Q1FY20 numbers led by higher-than-expected contribution from

Read Full Article

Hold Apollo Hospitals; target of Rs 1500: ICICI Direct

ICICI Direct’s research report on Apollo Hospitals Q1FY20 revenues grew 16.7% YoY to Rs 2229.2 crore (I-direct estimate: Rs

Read Full Article

Hold Balkrishna Industries; target of Rs 700: ICICI Direct

ICICI Direct’s research report on Balkrishna Industries Balkrishna Industries (BIL) reported a disappointing set of Q1FY20 numbers. Standalone revenue

Read Full Article

Hold Sun Pharmaceutical Industries; target of Rs 470: ICICI Direct

ICICI Direct’s research report on Sun Pharmaceutical Industries Q1FY20 revenues grew 15.9% YoY to Rs 8374.4 crore (I-direct estimate:

Read Full Article

Archives